Atypical haemolytic uremic syndrome secondary to acute pancreatitis: a unique presentation

Atypical haemolytic uraemic syndrome (aHUS) is a disease of complement dysregulation and can be fatal if not treated in a timely manner. Although normally associated with triggers such as infection or pregnancy, this case demonstrates acute pancreatitis as the triggering event. The patient’s initial...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2019-09, Vol.12 (9), p.e230822
Main Authors: Barish, Jacob, Kopparthy, Pallavi, Fletcher, Bradley
Format: Article
Language:English
Subjects:
Abdomen
Acute Disease
Adult
Anemia
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - therapeutic use
Atypical Hemolytic Uremic Syndrome - diagnosis
Atypical Hemolytic Uremic Syndrome - drug therapy
Atypical Hemolytic Uremic Syndrome - etiology
Biopsy
Case reports
Complement Inactivating Agents - administration & dosage
Complement Inactivating Agents - therapeutic use
Cysts
Diagnosis, Differential
Drug dosages
Family medical history
Hematology
Humans
Kidneys
Laboratories
Male
Monoclonal antibodies
Mutation
Nephrology
Pancreatitis
Pancreatitis - complications
Pancreatitis - diagnostic imaging
Physicians
Renal Insufficiency - etiology
Thrombocytopenia - etiology
Tomography, X-Ray Computed - methods
Treatment Outcome
Unusual Presentation of More Common Disease/Injury
Urinalysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atypical haemolytic uraemic syndrome (aHUS) is a disease of complement dysregulation and can be fatal if not treated in a timely manner. Although normally associated with triggers such as infection or pregnancy, this case demonstrates acute pancreatitis as the triggering event. The patient’s initial presentation of thrombocytopaenia and acute renal failure was first attributed to a systemic inflammatory response syndrome due to pancreatitis, but with detailed history and further laboratory investigation, we were able to show that patient was having symptoms associated with aHUS. On early recognition of aHUS, this patient was able to receive the proper standard of care with eculizumab and had a full recovery while preventing renal failure. When patients present with thrombocytopaenia and renal failure in acute pancreatitis, we want to ensure physicians keep aHUS on the differential.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2019-230822